Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00042653
Status:
COMPLETED
Last Update Posted:
2013-05-08
First Post:
2002-08-02
Brief Title:
A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Placebo-controlled Double-blind Multicenter Study to Assess the Efficacy and Safety of an Oral Calcimimetic Agent AMG 073 in Secondary Hyperparathyroidism of Chronic Kidney Disease Hemodialysis and Peritoneal Dialysis
Status:
COMPLETED
Status Verified Date:
2013-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This 6 month study will assess an investigational medication for patients on dialysis with secondary hyperparathyroidism The study will look at the effects on parathyroid hormone calcium and phosphorus levels
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None